Testosterone Is Not a Male Hormone

Testosterone is not a male hormone.

Men usually have higher levels of testosterone, but women make and use testosterone throughout life. It is part of normal female physiology, not an exception to it.

When testosterone declines, becomes less available, or is ignored clinically, some women notice changes in sexual function, strength, energy, motivation, recovery, and physical resilience. Those changes are often explained away as stress, aging, mood, relationship strain, or unrealistic expectations. Sometimes those factors are involved. Sometimes they are not enough to explain what has changed.

Women Make Testosterone

Women produce testosterone through the ovaries, adrenal glands, and local tissue conversion. It interacts with muscle, bone, brain, skin, sexual tissue, and metabolic pathways.

Describing testosterone as a male hormone has distorted the way many clinicians think about women’s health. The hormone is not male. The usual blood level is different by sex, but the physiology belongs to both men and women.

This distinction affects care. When men report loss of strength, drive, stamina, libido, and confidence, testosterone is usually part of the medical discussion. When women report similar changes, the conversation often moves first to stress, sleep, mood, caregiving, body image, or relationship dynamics.

Those issues can matter. They should be discussed with care. They should not automatically replace a hormone evaluation.

The Sexual Function Evidence

The strongest published evidence for testosterone therapy in women is for postmenopausal women with hypoactive sexual desire disorder, often called HSDD.

A 2019 systematic review and meta-analysis included 46 reports from 36 randomized controlled trials and 8,480 participants. Testosterone significantly improved satisfying sexual event frequency, desire, pleasure, arousal, orgasm, responsiveness, self-image, sexual concerns, and sexual distress in postmenopausal women.

The 2019 Global Consensus Position Statement, endorsed by major international societies, concluded that testosterone therapy at physiologic female dosing improves sexual function in postmenopausal women with HSDD. The evidence rating for this indication was Level I, Grade A.

This does not mean testosterone is appropriate for every woman with low libido. It does mean the evidence for properly selected women is stronger than many patients are led to believe.

Orgasm And Testosterone

Some papers and commentaries describe the evidence for orgasm as limited. That wording can be misleading without context.

Testosterone does not explain every aspect of orgasm. Pain, vaginal dryness, relationship distress, trauma, antidepressants, poor sleep, alcohol use, pelvic floor dysfunction, depression, anxiety, and inadequate stimulation can all affect sexual response.

In randomized trials of appropriately selected postmenopausal women with HSDD, orgasmic function improved as part of broader sexual function. The evidence does not support the idea that testosterone is irrelevant to orgasmic function. It supports a more careful conclusion: testosterone may help some women, within a broader clinical picture.

Beyond Libido

At HormoneSynergy®, testosterone is not viewed as a libido-only hormone.

Many women describe changes that do not fit neatly into one research endpoint. They report better drive, improved confidence, better recovery from exercise, better response to strength training, less flatness, more physical resilience, and a stronger sense of being present in their body.

These outcomes are clinically meaningful, but they should be discussed honestly. The strongest women-specific trial data are for sexual desire and sexual function. The broader questions involving muscle, bone, recovery, cardiovascular health, cognition, and long-term disease prevention are more complex.

Some of these effects are biologically plausible. Some are supported by clinical experience and androgen physiology. Some still need better trials in women.

Women do not need exaggerated claims. They need careful medicine that takes their symptoms seriously.

Muscle, Bone, And Aging

Aging is closely tied to loss of capacity. Strength, muscle, bone density, balance, recovery, sexual function, motivation, and independence all influence how a person ages.

Bone and muscle are hormonally responsive tissues. Estrogen matters. Protein matters. Resistance training matters. Vitamin D, thyroid function, sleep, inflammation, insulin sensitivity, medications, and injury history all matter.

Testosterone may also matter.

For women losing lean mass, struggling to recover from exercise, experiencing a decline in sexual function, or noticing a marked loss of drive and vitality, testosterone belongs in the clinical conversation. It should not be treated as a shortcut or a stand-alone answer. It should be considered as one part of a larger longevity plan.

Blood Levels Have Limits

Testosterone testing in women has limitations.

A low blood testosterone level does not automatically diagnose a clinical syndrome. A number in the reference range does not automatically mean a woman is functioning well. Many assays are less reliable at the lower concentrations seen in women. Sex hormone-binding globulin can affect how much testosterone is available to tissues. Oral estrogen can raise SHBG and reduce free testosterone availability.

For these reasons, HormoneSynergy® does not treat lab numbers in isolation.

Evaluation includes symptoms, medical history, menopause status, ovarian history, medications, sleep, strength, bone density, body composition, cardiometabolic risk, sexual health, laboratory data, treatment response, and side effects.

Safety And Monitoring

Testosterone therapy for women should be prescribed with restraint and monitored carefully.

The goal is not masculinization or supraphysiologic dosing. Careful treatment is different from high-dose hormone marketing, pellet-driven protocols, or one-size-fits-all prescribing.

Possible side effects can include acne, unwanted hair growth, scalp hair thinning, mood changes, voice changes, clitoral enlargement, and lipid changes depending on formulation and dose. Some effects may not fully reverse.

In Dr. Retzler’s practice, these problems are uncommon. That is one reason we emphasize conservative dosing, symptom tracking, lab monitoring, and dose adjustment over aggressive protocols.

At HormoneSynergy®, testosterone is considered in the context of dosing, symptom tracking, lab monitoring, and whole-person risk assessment. Women deserve access to appropriate treatment, and they also deserve the protection of careful prescribing.

Off-Label Treatment

There is currently no FDA-approved testosterone product for women in the United States.

This is a regulatory fact. It is not the same as saying testosterone has no evidence in women.

Women’s hormone care has been shaped by missing products, underfunded research, conservative labeling, and long-standing discomfort with female sexuality and midlife vitality. The absence of a female-specific FDA-approved product leaves clinicians and patients with off-label prescribing, dose adjustment, and careful monitoring.

That requires judgment. It should not become a reason to dismiss women or a reason to overprescribe.

The HormoneSynergy® Approach

At HormoneSynergy®, testosterone is evaluated as part of comprehensive hormone and longevity care.

We consider it alongside estrogen, progesterone, thyroid function, adrenal health, cardiometabolic risk, nutrition, resistance training, sleep, bone density, body composition, sexual health, and patient goals.

For many women in our practice, testosterone is part of restoring function. Not every woman needs it. Some women clearly do better when it is restored thoughtfully, dosed carefully, and monitored over time.

The larger issue is not whether testosterone is male or female. The issue is whether women’s loss of strength, desire, drive, recovery, and vitality is taken seriously enough to evaluate well.

At HormoneSynergy®, we believe it should be.

Related HormoneSynergy® Resources

• HormoneSynergy® Longevity Medicine Resource Library
• Bioidentical Hormone Therapy for Women and Men
• Optimal Aging Assessment
• Concierge Longevity Medicine
• DEXA Body Composition, Bone Density, and Visceral Fat
• CNS Vital Signs Neurocognitive Testing

References

• Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019.
• Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019.
• Parish SJ, Simon JA, Davis SR, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021.
• Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000.
• Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008.

Editorial Transparency

This article is educational and reflects the clinical perspective of HormoneSynergy® Clinic LLC. It is not a diagnosis, prescription, or replacement for individualized medical care. Testosterone therapy for women requires careful evaluation, appropriate dosing, monitoring, and discussion of risks, benefits, alternatives, and regulatory status.